PL439808A1 - Sposoby i kompozycje hodowli komórkowych do produkcji przeciwciał - Google Patents

Sposoby i kompozycje hodowli komórkowych do produkcji przeciwciał

Info

Publication number
PL439808A1
PL439808A1 PL439808A PL43980820A PL439808A1 PL 439808 A1 PL439808 A1 PL 439808A1 PL 439808 A PL439808 A PL 439808A PL 43980820 A PL43980820 A PL 43980820A PL 439808 A1 PL439808 A1 PL 439808A1
Authority
PL
Poland
Prior art keywords
compositions
production
methods
antibodies
cell cultures
Prior art date
Application number
PL439808A
Other languages
English (en)
Inventor
Yogender Kumar GOWTHAM
Sokha Susan LAY
Edmund G. Scarfo
Nandita VISHWANATHAN
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of PL439808A1 publication Critical patent/PL439808A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Abstract

Wynalazek przedstawia metody hodowli komórek do produkcji przeciwciała anty-α4β7, np. Wedolizumabu, jak również jego kompozycje.
PL439808A 2019-06-10 2020-06-10 Sposoby i kompozycje hodowli komórkowych do produkcji przeciwciał PL439808A1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962859596P 2019-06-10 2019-06-10
US201962859563P 2019-06-10 2019-06-10
PCT/US2020/037080 WO2020252082A1 (en) 2019-06-10 2020-06-10 Cell culture methods and compositions for antibody production

Publications (1)

Publication Number Publication Date
PL439808A1 true PL439808A1 (pl) 2022-12-05

Family

ID=73780813

Family Applications (1)

Application Number Title Priority Date Filing Date
PL439808A PL439808A1 (pl) 2019-06-10 2020-06-10 Sposoby i kompozycje hodowli komórkowych do produkcji przeciwciał

Country Status (14)

Country Link
US (1) US20220267448A1 (pl)
EP (1) EP3980068A4 (pl)
JP (1) JP2022536658A (pl)
KR (1) KR20220019725A (pl)
CN (4) CN117925711A (pl)
AU (1) AU2020291920A1 (pl)
BR (1) BR112021024852A2 (pl)
CA (1) CA3143246A1 (pl)
IL (1) IL288819A (pl)
MA (1) MA56130A (pl)
MX (1) MX2021015301A (pl)
PL (1) PL439808A1 (pl)
TW (1) TW202112819A (pl)
WO (1) WO2020252082A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023021532A1 (en) * 2021-08-20 2023-02-23 Dr. Reddy’S Laboratories Limited A process to produce a pharmaceutical composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP2221361A3 (en) * 1996-08-30 2011-02-09 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
EP1948691A1 (en) * 2005-11-17 2008-07-30 Millennium Pharmaceuticals, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH a4ß7INTEGRIN
US8911964B2 (en) * 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
EP2068923A4 (en) * 2007-03-30 2010-11-24 Medimmune Llc ANTIBODIES HAVING REDUCED DEAMIDATION PROFILES
MY169935A (en) * 2011-04-29 2019-06-18 Biocon Biologics India Ltd "a method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof"
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
HU231463B1 (hu) * 2015-08-04 2024-01-28 Richter Gedeon Nyrt. Módszer rekombináns proteinek galaktóz tartalmának növelésére
SG11201804259UA (en) * 2015-12-04 2018-06-28 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation

Also Published As

Publication number Publication date
WO2020252082A1 (en) 2020-12-17
EP3980068A4 (en) 2023-05-31
IL288819A (en) 2022-02-01
BR112021024852A2 (pt) 2022-02-15
CN117925711A (zh) 2024-04-26
CA3143246A1 (en) 2020-12-17
US20220267448A1 (en) 2022-08-25
CN117925710A (zh) 2024-04-26
CN114206383A (zh) 2022-03-18
CN117925709A (zh) 2024-04-26
MA56130A (fr) 2022-04-13
JP2022536658A (ja) 2022-08-18
KR20220019725A (ko) 2022-02-17
MX2021015301A (es) 2022-02-03
TW202112819A (zh) 2021-04-01
AU2020291920A1 (en) 2022-02-03
EP3980068A1 (en) 2022-04-13

Similar Documents

Publication Publication Date Title
CY1123642T1 (el) Αντισωματα enanti-pd-1
EA202192126A3 (ru) Способы сбора культур клеток млекопитающих
PH12018502456A1 (en) Anti-cd04 antibodies and their uses
MY198059A (en) Anti-ox40 antibodies and their uses
CO2019013838A2 (es) Método de fabricación de anticuerpos bispecíficos, anticuerpos bispecíficos y uso terapéutico de dichos anticuerpos
BR112016014022A2 (pt) anticorpos anti-cd3, ácido nucleico isolado, vetor, célula hospedeira, método de produção do anticorpo anti-cd3, imunoconjugado, composição, uso do anticorpo anti-cd3, métodos de tratamento, métodos de intensificação da função imune e kit
EA201890137A1 (ru) Среда для культивирования клеток с добавлением таурина и способы применения
MX2019003427A (es) Composiciones para cultivo celular y metodos para la produccion de polipeptidos.
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
PL439807A1 (pl) Sposoby oczyszczania przeciwciał i ich kompozycje
MX366112B (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
AR119997A1 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
BR112018014355A2 (pt) processos para a preparação de f-benzoxazinorifamicina i e para a preparação de 2-amino-5-fluorobenzeno-1,3-diol iii
EA202091349A1 (ru) Способы культивирования клеток
JOP20210015A1 (ar) تركيبات مضادات fcrn وطرق استخدامها
BR112018009097A8 (pt) spodoptera frugiperda resistente a vip3a
MX2021012984A (es) Anticuerpos y metodos para el tratamiento de la infeccion por influenza a.
BR112022012731A2 (pt) Anticorpo anti-ox40 e uso do mesmo
EA201791233A1 (ru) Материал стволовых клеток и способ его получения
PL439808A1 (pl) Sposoby i kompozycje hodowli komórkowych do produkcji przeciwciał
CL2021001118A1 (es) Métodos y cultivos para fabricar queso para pizza.
BR112023024837A2 (pt) Anticorpos anti-ccr8
EA202192893A1 (ru) Среда для культивирования эукариотических клеток
AU2017261305A8 (en) DNA monoclonal antibodies targeting influenza virus
UY37914A (es) Anticuerpo monoclonal contr il-5r